TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19345510

Group type: EXPERIMENTAL
Intervention: Acamprosate (1998 mg daily) during Detoxification Phase (5-14 days)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Acamprosate (1998 mg daily) during Rehabilitation Phase (after detoxification)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo during Detoxification Phase (5-14 days)
Number of subjects: 40
Study: 16983476

Group type: EXPERIMENTAL
Intervention: Synbiotic formula (Synbiotic 2000Forte)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Maltodextrin (placebo)
Number of subjects: 65
Study: 15014939

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training for 12 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control Group (not specified)
Number of subjects: 26
Study: 11170991

Group type: EXPERIMENTAL
Intervention: 1 dose of RTS,S/SBAS2
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 2 doses of RTS,S/SBAS2
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 3 standard doses of RTS,S/SBAS2
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 3 one-half doses of RTS,S/SBAS2
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 3 one-fifth doses of RTS,S/SBAS2
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no vaccine)
Number of subjects: 64
Study: 9779247

Group type: EXPERIMENTAL
Intervention: Topical and systemic medication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Serum tenascin-C measurement
Number of subjects: 0
Study: 8154950

Group type: EXPERIMENTAL
Intervention: Antibiotic consultant
Number of subjects: 482

Group type: COMPARATOR
Intervention: Physicians' orders
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Physician feedback
Number of subjects: 482
Study: 3337344

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% (pH, 5.5) 3 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Alkalinized bupivacaine 0.5% (pH, 7.05-7.15) 3 mg/kg
Number of subjects: 60
Study: 1347293

Group type: EXPERIMENTAL
Intervention: Right unilateral ECT
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Left unilateral ECT
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bilateral ECT
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intensive pharmacotherapy
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Crossover bilateral ECT
Number of subjects: 24

Group type: COMPARATOR
Intervention: ECT nonresponders
Number of subjects: 24
Study: 623041

Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (fat 24%, carbohydrate 58%, protein 18% of energy)
Number of subjects: 22

Group type: COMPARATOR
Intervention: High-fat diet (fat 47%, carbohydrate 35%, protein 18% of energy)
Number of subjects: 22
Study: 31836722

Group type: EXPERIMENTAL
Intervention: Permanent dermal matrix
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Temporary granulation-tissue-inducing dressing
Number of subjects: 10

Group type: COMPARATOR
Intervention: No dermal component (Control)
Number of subjects: 10
Study: 28233277

Group type: EXPERIMENTAL
Intervention: Autologous plasma coating of meshes prior to implantation
Number of subjects: 428

Group type: COMPARATOR
Intervention: Non-coated meshes
Number of subjects: 428
Study: 24448017

Group type: EXPERIMENTAL
Intervention: Supervised back and core exercise performed on duty, 2X/week, 24 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (n=28)
Number of subjects: 64
Study: 24392608

Group type: EXPERIMENTAL
Intervention: Folkloric dance program and screen time reduction curriculum
Number of subjects: 83
Study: 21725168

Group type: EXPERIMENTAL
Intervention: Stochastic whole body vibration (WBV) - 5 cycles on three days, each cycle consisting of 5 stimulus trains of 60 seconds duration (frequency 6.5 Hz) with 60 seconds resting time between stimuli.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham treatment - 1 Hz.
Number of subjects: 18
Study: 19408036

Group type: EXPERIMENTAL
Intervention: Andrographis paniculata (Paractin) tablets, 30% total andrographolides, administered three times a day for 14 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Andrographis paniculata (Paractin) tablets
Number of subjects: 60
Study: 17525777

Group type: COMPARATOR
Intervention: Lumbar facet joint nerve blocks using bupivacaine (Control Group I)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lumbar facet joint nerve blocks using bupivacaine and Sarapin (Group II)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lumbar facet joint nerve blocks using bupivacaine and steroids (Group III)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lumbar facet joint nerve blocks using bupivacaine, Sarapin, and steroids (Group IV)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-steroid group (Groups I and II)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Steroid group (Groups III and IV)
Number of subjects: 60
Study: 12571487

Group type: EXPERIMENTAL
Intervention: Patients with organic pathology
Number of subjects: 138

Group type: COMPARATOR
Intervention: Patients without organic pathology
Number of subjects: 138
Study: 11141929

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: No antibiotic therapy (Control)
Number of subjects: 40
Study: 8789903

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 445

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 445
Study: 1281960

Group type: EXPERIMENTAL
Intervention: Swedish version of the Positive and Negative Syndrome Scale (PANSS)
Number of subjects: 88
Study: 6242150

Group type: EXPERIMENTAL
Intervention: HB vaccine (5 micrograms, 3 injections at one-month intervals plus a booster after one year)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: HB vaccine (5 micrograms, 2 doses given at intervals of 2 or 6 months plus a booster after one year)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: HB vaccine
Number of subjects: 309

Group type: COMPARATOR
Intervention: HB vaccine and DT-polio vaccine administered simultaneously
Number of subjects: 309
Study: 31326975

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation combined with fiberoptic bronchoalveolar lavage
Number of subjects: 81
Study: 27659296

Group type: EXPERIMENTAL
Intervention: Resorbable membrane (RES)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Titanium-reinforced non-resorbable membrane (N-RES)
Number of subjects: 27
Study: 25822479

Group type: EXPERIMENTAL
Intervention: Perospirone or aripiprazole
Number of subjects: 100
Study: 22822181

Group type: EXPERIMENTAL
Intervention: Aquatic exercise in a chest-high pool
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 40
Study: 22146169

Group type: EXPERIMENTAL
Intervention: Polyglactin (vicryl) mesh
Number of subjects: 150

Group type: COMPARATOR
Intervention: Polypropylene mesh
Number of subjects: 150
Study: 19249739

Group type: EXPERIMENTAL
Intervention: Simulated training
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard training
Number of subjects: 34
Study: 16479196

Group type: EXPERIMENTAL
Intervention: Native Escherichia coli L‐asparaginase (Crasnitin; n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: L‐asparaginase derived from Erwinia chrysanthemi (Erwinase; n = 10)
Number of subjects: 20
Study: 14739798

Group type: EXPERIMENTAL
Intervention: Surgical attire
Number of subjects: 60

Group type: COMPARATOR
Intervention: Antichemical protective gear
Number of subjects: 60
Study: 11314565

Group type: EXPERIMENTAL
Intervention: Parent Training (PT; n = 30)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Parent Counseling and Support (PCO&S; n = 28)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Waiting-list control group (n = 20)
Number of subjects: 78
Study: 9422294

Group type: EXPERIMENTAL
Intervention: Desflurane discontinued first (Group 1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nitrous oxide discontinued first (Group 2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 8368679

Group type: EXPERIMENTAL
Intervention: Clonidine (CI)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Arginine aspartate (AA)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Ornithine alpha-ketoglutarate (OKG)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Cyproheptadine (Cp)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 3954392

Group type: EXPERIMENTAL
Intervention: 10(6) IU of IFN
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: 10(5) IU of IFN
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Interferon administration
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Treatment discontinuation due to adverse reactions
Number of subjects: 237
Study: 31515201

Group type: EXPERIMENTAL
Intervention: IVC ligation
Number of subjects: 443
Study: 29219480

Group type: EXPERIMENTAL
Intervention: Projective measurements (PMs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General measurements in dimension two or three
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Projective measurements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two-qubit Werner states
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measurements
Number of subjects: 0
Study: 26000551

Group type: EXPERIMENTAL
Intervention: Black cohosh
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 23163735

Group type: EXPERIMENTAL
Intervention: Intensive Life style Intervention (ILI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional obesity therapy (COT)
Number of subjects: 60
Study: 21756014

Group type: EXPERIMENTAL
Intervention: Shared medical appointments (SMA)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 103
Study: 17964674

Group type: EXPERIMENTAL
Intervention: Peripheral endothelial dysfunction
Number of subjects: 0
Study: 17162836

Group type: EXPERIMENTAL
Intervention: Unannounced visits to primary schools and health clinics
Number of subjects: 0
Study: 15625442

Group type: EXPERIMENTAL
Intervention: Early enteral feeding within 24 hours of injury
Number of subjects: 0

Group type: COMPARATOR
Intervention: Late enteral feeding after 7 days of injury
Number of subjects: 0
Study: 10768275

Group type: EXPERIMENTAL
Intervention: Captopril (ACE inhibitor)
Number of subjects: 696

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 696
Study: 9389821

Group type: EXPERIMENTAL
Intervention: Hysteroscopic tubal catheterization
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Microsurgical repair
Number of subjects: 43

Group type: COMPARATOR
Intervention: Reversal of elective sterilization
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both cornual-isthmic blockage-treated groups
Number of subjects: 43
Study: 7951480

Group type: EXPERIMENTAL
Intervention: Bombesin infusion
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 18
Study: 3311923

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (160 mg/day)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Megestrol acetate/tamoxifen (20 mg/day)
Number of subjects: 33
Study: 29763612

Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment
Number of subjects: 60
Study: 28481169

Group type: EXPERIMENTAL
Intervention: desipramine/naltrexone
Number of subjects: 88

Group type: COMPARATOR
Intervention: desipramine/placebo
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: paroxetine/naltrexone
Number of subjects: 88

Group type: COMPARATOR
Intervention: paroxetine/placebo
Number of subjects: 88
Study: 26148327

Group type: EXPERIMENTAL
Intervention: Nurse-led psychoeducational intervention (brief or extensive)
Number of subjects: 484

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 484
Study: 24284856

Group type: EXPERIMENTAL
Intervention: Transdermal VALE-ibuprofen (200 mg ibuprofen, 2.0 grams of drug product applied twice daily for 14 days)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Transdermal VALE-ibuprofen
Number of subjects: 64
Study: 20955821

Group type: EXPERIMENTAL
Intervention: Individualized active-maintenance intervention over 48 months
Number of subjects: 1277

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1277
Study: 18317064

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study: 16126290

Group type: EXPERIMENTAL
Intervention: Nasal oxygen (4 L/min)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) (mean 9.3 cm H(2)O)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Bilevel positive airway pressure (BiPAP) (mean 12.0/5.3 cm H(2)O)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: High frequency jet ventilation (HFJV) (60-80 breaths per minute)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 11
Study: 14571151

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (paroxetine)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Serotonin-noradrenaline reuptake inhibitor (venlafaxine)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Not applicable (absence of previous therapies, moderate baseline severity of obsessive-compulsive symptoms, low Hamilton Depressive Rating Scale scores)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 150
Study: 11056332

Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg once daily
Number of subjects: 668

Group type: COMPARATOR
Intervention: Tamoxifen 20 mg daily
Number of subjects: 668
Study: 7740933

Group type: EXPERIMENTAL
Intervention: Occlusal adjustment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Comfort only (Control)
Number of subjects: 50
Study: 1982059

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg/day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oxprenolol (80 mg/day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg/day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Celiprolol (200 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 233458

Group type: EXPERIMENTAL
Intervention: Intrapleural administration of Corynebacterium parvum (7 mg)
Number of subjects: 475

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 475
Study: 31977632

Group type: COMPARATOR
Intervention: no-exercise control (n = 42)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: low-amount, low-intensity exercise (LALI; n = 39)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: high-amount, low-intensity exercise (HALI; n = 51)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: high-amount, high-intensity exercise (HAHI; n = 31)
Number of subjects: 163
Study: 30309816

Group type: EXPERIMENTAL
Intervention: Rufinamide (≤45 mg/kg/day)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Any other AED
Number of subjects: 37
Study: 28802307

Group type: EXPERIMENTAL
Intervention: Lower-fat, higher-carbohydrate diet (20% fat, 66% carbohydrate, 14% protein)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Moderate-fat, moderate-carbohydrate diet (30% fat, 56% carbohydrate, 14% protein)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Higher-fat, lower-carbohydrate diet (40% fat, 46% carbohydrate, 14% protein)
Number of subjects: 300
Study: 26660938

Group type: EXPERIMENTAL
Intervention: Visomitin eye drops, self-administered three times daily (TID) for 6 weeks
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo, self-administered three times daily (TID) for 6 weeks
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Visomitin eye drops
Number of subjects: 240
Study: 23260618

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (30 min daily for 7 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 60
Study: 21189270

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin (45mg/kg/day for 3 days)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 900
Study: 18650545

Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg/day for 4 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo for 4 days
Number of subjects: 36
Study: 17143127

Group type: EXPERIMENTAL
Intervention: Nutritional intervention-physical exercise program
Number of subjects: 75

Group type: COMPARATOR
Intervention: Nutritional intervention program
Number of subjects: 75
Study: 12625081

Group type: EXPERIMENTAL
Intervention: Lateral decubitus 'biopsy‐side‐down' position
Number of subjects: 87

Group type: COMPARATOR
Intervention: Biopsy‐site‐dependent position (lying directly on the skin puncture site)
Number of subjects: 87
Study: 10845809

Group type: EXPERIMENTAL
Intervention: Day 1 + 8 schedule (5FU and CTX 500mg/m2 day 1, epirubicin 40 mg/m2 day 1 and 8)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Day 1 schedule (5FU, CTX 500 mg/m2 and epirubicin 80 mg/m2 day 1)
Number of subjects: 104
Study: 9209791

Group type: EXPERIMENTAL
Intervention: MLD/PD-heterozygotes
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: MLD-patients
Number of subjects: 3

Group type: COMPARATOR
Intervention: PD/PD-homozygotes
Number of subjects: 3
Study: 8271802

Group type: EXPERIMENTAL
Intervention: Outpatient treatment focused on drinking reduction techniques
Number of subjects: 0
Study: 2961316

Group type: EXPERIMENTAL
Intervention: Regular chloroquine (10 mg base kg‐1)
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Enteric-coated chloroquine (10 mg base kg‐1)
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Amodiaquine (10 mg base kg‐1)
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Enteric-coated ferrous sulphate (300 mg tablet)
Number of subjects: 619
Study: 30029600

Group type: EXPERIMENTAL
Intervention: Environmental nudges such as food product placement or promotion
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Nudges and a tailored physical activity app that provides time- and context-specific feedback
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Pricing interventions, nudges, and the physical activity app
Number of subjects: 1000

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: All interventions combined
Number of subjects: 1000
Study: 26686313

Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg oral daily for 5 years)
Number of subjects: 2980

Group type: COMPARATOR
Intervention: Tamoxifen (20 mg oral daily for 5 years)
Number of subjects: 2980

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 2980

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 2980
Study: 24927611

Group type: COMPARATOR
Intervention: sTNF‐R1 levels in patients with IGT and DM
Number of subjects: 54

Group type: COMPARATOR
Intervention: TGF‐β1 levels in patients with IGT and DM
Number of subjects: 54

Group type: COMPARATOR
Intervention: Leptin, HGF, and TNF‐α levels
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Cytokine levels in Child‐Pugh classification groups B or C
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Correlations between sTNF‐R1 and HOMA2‐IR
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Correlations between leptin and HOMA2‐IR
Number of subjects: 54
Study: 22880214

Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC) - four 5 min cycles of transient upper limb ischaemia/reperfusion
Number of subjects: 2070

Group type: COMPARATOR
Intervention: Control group - four cycles of blood pressure cuff inflation/deflation at a dummy arm
Number of subjects: 2070
Study: 20359355

Group type: EXPERIMENTAL
Intervention: Executive functions assessed using the Trail Making Test (Part B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Executive functions assessed using the Digits Verbal Span Backward Test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Global cognition assessed using the Mini-Mental State Examination (MMSE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Resistance training (not detailed in the abstract)
Number of subjects: 0
Study: 18787198

Group type: EXPERIMENTAL
Intervention: Mobile teleconsultation
Number of subjects: 223

Group type: COMPARATOR
Intervention: Hospital-based teleconsultation
Number of subjects: 223
Study: 15917033

Group type: EXPERIMENTAL
Intervention: Sun Protection is Fun! (S.P.F.) intervention including a video, newsletters, and handbooks
Number of subjects: 384
Study: 12873112

Group type: EXPERIMENTAL
Intervention: Modified pen grip
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-pen grip
Number of subjects: 0
Study: 10574478

Group type: EXPERIMENTAL
Intervention: Formula supplemented with arginine, omega-3 fatty acids, and RNA (verum group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control enteral formula (control group)
Number of subjects: 50
Study: 8923091

Group type: EXPERIMENTAL
Intervention: Interferon-gamma (Imukin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 1426657

Group type: EXPERIMENTAL
Intervention: IMOCURR
Number of subjects: 423

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study: 4047104

Group type: EXPERIMENTAL
Intervention: Combined estrogen‐progestogen (high-dose: 4 mg of estradiol)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Combined estrogen‐progestogen (other doses)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 136
Study: 29552762

Group type: EXPERIMENTAL
Intervention: Carbon nanoparticle tracer for intraoperative dye detection and positioning
Number of subjects: 80

Group type: COMPARATOR
Intervention: Surgery (control group)
Number of subjects: 80
Study: 27532508

Group type: EXPERIMENTAL
Intervention: Bone Marrow (BM) transplantation
Number of subjects: 551

Group type: COMPARATOR
Intervention: Peripheral Blood (PB) transplantation
Number of subjects: 551
Study: 24408441

Group type: EXPERIMENTAL
Intervention: Stress group (SG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 22543889

Group type: EXPERIMENTAL
Intervention: Kicking and treadmill stepping intervention
Number of subjects: 16

Group type: COMPARATOR
Intervention: No-training control condition
Number of subjects: 16